PL1890732T3 - Preparaty zwężające naczynia krwionośne do podawania miejscowego i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej - Google Patents

Preparaty zwężające naczynia krwionośne do podawania miejscowego i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej

Info

Publication number
PL1890732T3
PL1890732T3 PL06773476T PL06773476T PL1890732T3 PL 1890732 T3 PL1890732 T3 PL 1890732T3 PL 06773476 T PL06773476 T PL 06773476T PL 06773476 T PL06773476 T PL 06773476T PL 1890732 T3 PL1890732 T3 PL 1890732T3
Authority
PL
Poland
Prior art keywords
radiotherapy
methods
cells during
cancer chemotherapy
during cancer
Prior art date
Application number
PL06773476T
Other languages
English (en)
Inventor
William E. Fahl
Arnold E. Ruoho
Minesh Mehta
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of PL1890732T3 publication Critical patent/PL1890732T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
PL06773476T 2005-06-17 2006-06-19 Preparaty zwężające naczynia krwionośne do podawania miejscowego i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej PL1890732T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69157105P 2005-06-17 2005-06-17
PCT/US2006/023708 WO2006138691A1 (en) 2005-06-17 2006-06-19 Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
EP06773476.4A EP1890732B1 (en) 2005-06-17 2006-06-19 Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy

Publications (1)

Publication Number Publication Date
PL1890732T3 true PL1890732T3 (pl) 2018-11-30

Family

ID=37570784

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13157485T PL2656860T3 (pl) 2005-06-17 2006-06-19 Preparaty środka zwężającego naczynia i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej
PL06773476T PL1890732T3 (pl) 2005-06-17 2006-06-19 Preparaty zwężające naczynia krwionośne do podawania miejscowego i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13157485T PL2656860T3 (pl) 2005-06-17 2006-06-19 Preparaty środka zwężającego naczynia i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej

Country Status (15)

Country Link
US (4) US8114914B2 (pl)
EP (2) EP1890732B1 (pl)
JP (4) JP5756250B2 (pl)
CN (3) CN103948927B (pl)
AU (1) AU2006261358B2 (pl)
CA (1) CA2611496C (pl)
DK (2) DK2656860T3 (pl)
ES (2) ES2880624T3 (pl)
HK (2) HK1200087A1 (pl)
HU (2) HUE054887T2 (pl)
IL (2) IL191869A (pl)
PL (2) PL2656860T3 (pl)
PT (2) PT1890732T (pl)
TR (1) TR201809015T4 (pl)
WO (1) WO2006138691A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU2003220125B2 (en) 2002-03-20 2006-06-15 Mannkind Corporation Inhalation apparatus
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
EP2322180B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Diketopiperazine salts for drug delivery
US8114914B2 (en) * 2005-06-17 2012-02-14 Wisconsin Alumni Research Foundation Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
RU2390325C2 (ru) 2005-09-14 2010-05-27 Маннкайнд Корпорейшн Способ приготовления лекарственного препарата, основанный на увеличении сродства активных агентов к поверхностям кристаллических микрочастиц
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
US8785396B2 (en) * 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
US8636001B2 (en) 2008-06-13 2014-01-28 Mannkind Corporation Dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2609954T3 (da) 2008-06-20 2022-02-14 Mannkind Corp Interaktivt apparat til realtidsafbildning af inhalationspræstationer
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
EP2165706A1 (en) * 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
CN102647979B (zh) 2009-06-12 2015-03-04 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
EP2582421A1 (en) 2010-06-21 2013-04-24 MannKind Corporation Dry powder drug delivery system and methods
WO2012135765A2 (en) 2011-04-01 2012-10-04 Mannkind Corporation Blister package for pharmaceutical cartridges
AU2012262947A1 (en) * 2011-06-02 2014-01-16 Procertus Biopharm, Inc. Formulation of small adrenergic agonist salt forms in organic solvents
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
SG11201507564PA (en) 2013-03-15 2015-10-29 Mannkind Corp Microcrystalline diketopiperazine compositions and methods
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
JP6829196B2 (ja) 2014-11-14 2021-02-10 フォリア・インターナショナル 脱毛症を予防するためのシステムおよび方法
US10064816B2 (en) 2015-06-11 2018-09-04 ReJoy Treatment of sexual dysfunction
WO2019014518A1 (en) * 2017-07-14 2019-01-17 Galderma Research And Development METHODS AND COMPOSITIONS FOR REDUCING ADVERSE EFFECTS OF CHEMOTHERAPEUTIC TREATMENTS
CN111328284A (zh) 2017-08-07 2020-06-23 芬奇治疗公司 用于维持和恢复健康的肠道屏障的组合物和方法
WO2020113028A1 (en) * 2018-11-27 2020-06-04 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
WO2021084541A1 (en) * 2019-10-31 2021-05-06 Sol-Gel Technologies Ltd. Treatment of hair loss disorders with a topical egfr inhibitor
WO2023130086A1 (en) * 2021-12-31 2023-07-06 Jss Research, Llc Compositions and methods for topical treatment of vascular conditions
WO2023166274A1 (en) 2022-03-04 2023-09-07 Vasodynamics Limited Topical compositions and methods

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2414918A (en) * 1941-09-23 1947-01-28 Abramson Harold Alexander Solutions for the improved nebulization therapy of the lungs and bronchioles
US2774789A (en) * 1947-10-24 1956-12-18 Sterling Drug Inc 1-arterenol and its acid-addition salts and preparation thereof
US2919230A (en) * 1953-10-29 1959-12-29 Rohm & Haas Hydrophilic base therapeutic compositions comprising cation-exchange resin
BE555319A (pl) * 1956-03-21 1900-01-01
US3039922A (en) * 1959-08-17 1962-06-19 Carter Prod Inc Method of administering tablets having decongestant and anti-histaminic activity
US3134720A (en) * 1962-06-27 1964-05-26 Bristol Myers Co Medicated gels
US3574859A (en) * 1968-07-05 1971-04-13 Carl M Kosti Process for the treatment of hypertrophied gums
GB2122892B (en) * 1982-07-02 1986-01-29 Squibb & Sons Inc Nystantin pastille formulation
SE457055B (sv) * 1986-08-18 1988-11-28 Ferring Ab Topisk straalskyddsgel foer mukosa innehaallande kaerlsammandragande substanser
US4853216A (en) * 1987-04-02 1989-08-01 Bristol-Myers Company Process and composition for the topical application of alpha1 adrenergic agonist for pilomotor effects
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5013716A (en) 1988-10-28 1991-05-07 Warner-Lambert Company Unpleasant taste masking compositions and methods for preparing same
US5461042A (en) * 1988-12-30 1995-10-24 Loria; Roger M. Regulation of the immune system
US5374645A (en) * 1990-01-22 1994-12-20 Ciba-Geigy Corporation Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol
US5260292A (en) * 1991-03-05 1993-11-09 Marvin S. Towsend Topical treatment of acne with aminopenicillins
JPH04327533A (ja) 1991-04-23 1992-11-17 Lion Corp 抗アレルギー用粘膜局所投与剤
US5534242A (en) 1994-05-02 1996-07-09 Henry; Richard A. Lidocaine-vasoconstrictor aerosol preparation
US5585398A (en) * 1994-07-15 1996-12-17 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
NL9401183A (nl) 1994-07-19 1996-03-01 Nederland Ptt Modulator/demodulatorinrichting voor koppeling van een dataterminal met een zend/ontvanginrichting, alsmede werkwijzen voor het tot stand brengen van een dataverbinding tussen een eerste en een tweede modulator/demodulatorinrichting.
GB9422571D0 (en) 1994-11-09 1995-01-04 Whitehall Lab Ltd Haemorrihoidal compositions and method of use
CA2154979A1 (en) 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
AU728889C (en) 1996-12-23 2001-08-02 S.L.A. Pharma Ag Pharmaceutical composition for treating fecal incontinence and anal itch
GB2370989A (en) 2001-01-16 2002-07-17 Btg Int Ltd Piperine analogues for the treatment of skin conditions
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
JP2001131085A (ja) * 1999-08-25 2001-05-15 Saitama Daiichi Seiyaku Kk 経皮・経粘膜吸収用の医薬組成物
ES2305057T3 (es) * 2000-02-28 2008-11-01 Pharmakodex Limited Dispositivo para la administracion de farmacos orales.
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
WO2002030400A1 (fr) 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
JP2004521111A (ja) 2001-01-25 2004-07-15 ユーロ−セルティーク，エス．エイ． 局所麻酔薬および使用法
CA2441352C (en) 2001-02-15 2010-05-25 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US20040176359A1 (en) 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20020192273A1 (en) 2001-06-15 2002-12-19 Teri Buseman Therapeutic patch useful for the treatment of hemorrhoids
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
JP4544391B2 (ja) * 2001-12-28 2010-09-15 ライオン株式会社 眼科用組成物
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
WO2005014524A2 (en) * 2003-08-07 2005-02-17 Wisconsin Alumni Research Foundation Amino thiol compounds and compositions for use in conjunction with cancer therapy
EP1656102A2 (en) 2003-08-21 2006-05-17 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
US20070219253A1 (en) * 2003-09-17 2007-09-20 Gul Balwani Decongestant / antihistaminic / expectorant compositions
US20050226922A1 (en) 2004-04-13 2005-10-13 Mahmoud Ameri Apparatus and method for transdermal delivery of fentanyl-based agents
US8114914B2 (en) * 2005-06-17 2012-02-14 Wisconsin Alumni Research Foundation Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy

Also Published As

Publication number Publication date
EP1890732A4 (en) 2010-07-07
US8247457B2 (en) 2012-08-21
US8114914B2 (en) 2012-02-14
IL191869A0 (en) 2011-08-01
IL232904A0 (en) 2014-07-31
DK2656860T3 (da) 2021-07-26
US20070077219A1 (en) 2007-04-05
US11197836B2 (en) 2021-12-14
CA2611496C (en) 2015-07-28
US20160136113A1 (en) 2016-05-19
US20120316246A1 (en) 2012-12-13
ES2880624T3 (es) 2021-11-25
AU2006261358B2 (en) 2012-05-31
CN101198362B (zh) 2014-03-12
EP2656860B1 (en) 2021-05-05
PT1890732T (pt) 2018-07-02
CN107496925A (zh) 2017-12-22
HUE054887T2 (hu) 2021-10-28
IL232904A (en) 2015-11-30
EP1890732B1 (en) 2018-03-28
DK1890732T3 (en) 2018-07-02
HUE038177T2 (hu) 2018-09-28
IL191869A (en) 2014-06-30
HK1245143A1 (zh) 2018-08-24
JP2015098496A (ja) 2015-05-28
EP1890732A1 (en) 2008-02-27
HK1200087A1 (en) 2015-07-31
AU2006261358A1 (en) 2006-12-28
JP5756250B2 (ja) 2015-07-29
EP2656860A1 (en) 2013-10-30
PT2656860T (pt) 2021-07-28
CA2611496A1 (en) 2006-12-28
CN101198362A (zh) 2008-06-11
JP6348437B2 (ja) 2018-06-27
ES2675228T3 (es) 2018-07-09
CN103948927A (zh) 2014-07-30
PL2656860T3 (pl) 2021-11-08
TR201809015T4 (tr) 2018-07-23
JP2018203788A (ja) 2018-12-27
JP2016155880A (ja) 2016-09-01
CN103948927B (zh) 2017-11-07
JP6473103B2 (ja) 2019-02-20
WO2006138691A1 (en) 2006-12-28
US20110218223A1 (en) 2011-09-08
JP2008543876A (ja) 2008-12-04

Similar Documents

Publication Publication Date Title
HK1245143A1 (zh) 在癌症化療和放療時保護細胞的局部血管收縮劑製品和方法
EP1967209A4 (en) THERAPEUTIC AGENT AGAINST PROSTATE CANCER
EP1909832A4 (en) ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY
WO2008054726A3 (en) Targeting nbs1-atm interaction to sensitize cancer cells to radiotherapy and chemotherapy
IL211861A0 (en) Methods and aparatus for providing ballistic protection
SG133592A1 (en) Methods for treating prostate cancer with herbal compositions
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
EP1874342A4 (en) COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY
HK1077583A1 (en) Cudr as biomarker for cancer progression and therapeutic response
IL185463A0 (en) Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
IL176919A0 (en) Methods and compositions for treating cancer
MXPA02010866A (es) Composiciones y metodos para proteger celulas durante la quimioterapia y radioterapia contra el cancer.
GB0418328D0 (en) Cancer methods and medicaments
AU2003258061A8 (en) Therapeutic inhibitionof protein kinases in cancer cells
EP2121988A4 (en) SURVIVAL AND RECIPIENT OF PROSTATE CANCER
EP1773883A4 (en) PRODUCTION OF ANTICANCER ANTIBODIES USING MASKED CANCER CELLS AS IMMUNOGENS
EP2005954B8 (en) Kit for cancer therapy and pharmaceutical composition for cancer therapy
EP1599572A4 (en) COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY
EP1977247A4 (en) METHODS OF DIAGNOSING AND TREATING PROSTATE CANCER
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
HK1110224A1 (en) Therapeutic agent for cancer
EP1782827A4 (en) PEPTIDE VACCINE FOR THE TREATMENT OF CANCER
AU2005339587A8 (en) Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
AU2003271457A8 (en) Methods for detecting prostate cancer
AU2002319792A1 (en) Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy